These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 21132257)

  • 1. Personalized treatment in the eradication therapy for Helicobacter pylori.
    Jinda S; Nakatani K; Nishioka J; Yasuda K; Soya Y; Hayashi A; Wada H; Nobori T
    Int J Mol Med; 2011 Feb; 27(2):255-61. PubMed ID: 21132257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effect of CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with rabeprazole-based triple therapy in Chinese].
    He XX; Zhao YH; Hao YT
    Zhonghua Nei Ke Za Zhi; 2004 Jan; 43(1):13-5. PubMed ID: 14990013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tailored eradication therapy based on fecal Helicobacter pylori clarithromycin sensitivities.
    Kawai T; Yamagishi T; Yagi K; Kataoka M; Kawakami K; Sofuni A; Itoi T; Sakai Y; Moriyasu F; Osaka Y; Takagi Y; Aoki T; Rimbara E; Noguchi N; Sasatsu M
    J Gastroenterol Hepatol; 2008 Dec; 23 Suppl 2():S171-4. PubMed ID: 19120893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of CYP2C19 and MDR1 genotype on the eradication rate of Helicobacter pylori infection by triple therapy with pantoprazole, amoxycillin and clarithromycin.
    Oh JH; Dong MS; Choi MG; Yoo HW; Lee SB; Park YI; Chung IS
    J Gastroenterol Hepatol; 2009 Feb; 24(2):294-8. PubMed ID: 18823430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Development and clinical application of invader assay--detection of resistant mutation to clarithromycin in Helicobacter pylori].
    Egashira T
    Rinsho Byori; 2006 Feb; 54(2):176-83. PubMed ID: 16548239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effectiveness of eradication regimen based on the bacterial susceptibility and CYP2C19 genotype in children with refractory
    Zhang YD; Dong QW; Zhang SH; Gu F; Zhang Y; Song HB; Zuo NY; Zhang SS; Ma L; Ding ZL
    Zhonghua Er Ke Za Zhi; 2020 Jan; 58(1):41-45. PubMed ID: 31905475
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin.
    Furuta T; Shirai N; Takashima M; Xiao F; Hanai H; Sugimura H; Ohashi K; Ishizaki T; Kaneko E
    Clin Pharmacol Ther; 2001 Mar; 69(3):158-68. PubMed ID: 11240980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gastric Juice-Based Real-Time PCR for Tailored
    Peng X; Song Z; He L; Lin S; Gong Y; Sun L; Zhao F; Gu Y; You Y; Zhou L; Zhang J
    Int J Med Sci; 2017; 14(6):595-601. PubMed ID: 28638276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influences of proinflammatory and anti-inflammatory cytokine polymorphisms on eradication rates of clarithromycin-sensitive strains of Helicobacter pylori by triple therapy.
    Sugimoto M; Furuta T; Shirai N; Ikuma M; Hishida A; Ishizaki T
    Clin Pharmacol Ther; 2006 Jul; 80(1):41-50. PubMed ID: 16815316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori.
    Tanigawara Y; Aoyama N; Kita T; Shirakawa K; Komada F; Kasuga M; Okumura K
    Clin Pharmacol Ther; 1999 Nov; 66(5):528-34. PubMed ID: 10579481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection.
    Take S; Mizuno M; Ishiki K; Nagahara Y; Yoshida T; Inaba T; Yamamoto K; Okada H; Yokota K; Oguma K; Shiratori Y
    Am J Gastroenterol; 2003 Nov; 98(11):2403-8. PubMed ID: 14638340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of tailored Helicobacter pylori eradication treatment based on clarithromycin susceptibility and maintenance of acid secretion.
    Sugimoto M; Uotani T; Sahara S; Ichikawa H; Yamade M; Sugimoto K; Furuta T
    Helicobacter; 2014 Aug; 19(4):312-8. PubMed ID: 24690010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Usefulness of detection of clarithromycin-resistant Helicobacter pylori from fecal specimens for young adults treated with eradication therapy.
    Osaki T; Mabe K; Zaman C; Yonezawa H; Okuda M; Amagai K; Fujieda S; Goto M; Shibata W; Kato M; Kamiya S
    Helicobacter; 2017 Oct; 22(5):. PubMed ID: 28544222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Rapid detection of clarithromycin resistant Helicobacter pylori from children's gastric biopsy specimens by polymerase chain reaction-restriction fragment length polymorphism].
    Yan WH; Chen J; Yu JD; Li ZY; Huang XL; Zhang XP
    Zhonghua Er Ke Za Zhi; 2009 Nov; 47(11):848-51. PubMed ID: 20078998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors affecting first-line triple therapy of Helicobacter pylori including CYP2C19 genotype and antibiotic resistance.
    Lee JY; Kim N; Kim MS; Choi YJ; Lee JW; Yoon H; Shin CM; Park YS; Lee DH; Jung HC
    Dig Dis Sci; 2014 Jun; 59(6):1235-43. PubMed ID: 24599773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of MDR1 C3435T polymorphism on cure rates of Helicobacter pylori infection by triple therapy with lansoprazole, amoxicillin and clarithromycin in relation to CYP 2C19 genotypes and 23S rRNA genotypes of H. pylori.
    Furuta T; Sugimoto M; Shirai N; Matsushita F; Nakajima H; Kumagai J; Senoo K; Kodaira C; Nishino M; Yamade M; Ikuma M; Watanabe H; Umemura K; Ishizaki T; Hishida A
    Aliment Pharmacol Ther; 2007 Sep; 26(5):693-703. PubMed ID: 17697203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of CYP2C19 polymorphism and Helicobacter pylori genotype determined from gastric tissue samples on response to triple therapy for H pylori infection.
    Furuta T; Sagehashi Y; Shirai N; Sugimoto M; Nakamura A; Kodaira M; Kenmotsu K; Nagano M; Egashira T; Ueda K; Yoneyama M; Ohashi K; Ishizaki T; Hishida A
    Clin Gastroenterol Hepatol; 2005 Jun; 3(6):564-73. PubMed ID: 15952098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinical role of cytochrome p450 genotypes in Helicobacter pylori management.
    Sapone A; Vaira D; Trespidi S; Perna F; Gatta L; Tampieri A; Ricci C; Cantelli-Forti G; Miglioli M; Biagi GL; Paolini M
    Am J Gastroenterol; 2003 May; 98(5):1010-5. PubMed ID: 12809821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of CYP2C19 Gene Polymorphisms on Proton Pump Inhibitor, Amoxicillin, and Levofloxacin Triple Therapy for Eradication of Helicobacter Pylori.
    Lin YA; Wang H; Gu ZJ; Wang WJ; Zeng XY; Du YL; Ying SS; Zhang BH
    Med Sci Monit; 2017 Jun; 23():2701-2707. PubMed ID: 28577017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of CYP2C19 functional polymorphism on Helicobacter pylori eradication.
    Ozdil B; Akkiz H; Bayram S; Bekar A; Akgöllü E; Sandikçi M
    Turk J Gastroenterol; 2010 Mar; 21(1):23-8. PubMed ID: 20533108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.